NCT03091192 2026-01-23Savolitinib vs. Sunitinib in MET-driven PRCC.AstraZenecaPhase 3 Active not recruiting60 enrolled 15 charts
NCT06111235 2026-01-12A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTCG Oncology, Inc.Phase 3 Active not recruiting367 enrolled
NCT01310803 2017-10-05Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the BladderEndo PharmaceuticalsPhase 3 Terminated1 enrolled 5 charts
NCT00384891 2014-10-07Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder CancerMedical Enterprises Europe B.V.Phase 3 Terminated190 enrolled